| Document |
Document Title |
|
WO/2024/080373A1 |
This reagent for measuring activated partial thromboplastin time contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a structural unit. This blood coagulation time regulator for a lupus anticoagulant-positive blood spec...
|
|
WO/2024/080371A1 |
This blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII for activated partial thromboplastin time measurement uses, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphoryl...
|
|
WO/2024/080736A1 |
The present invention provides a feature related to a cored tablet combination preparation comprising clopidogrel or a pharmaceutically acceptable salt thereof and ilaprazole as active ingredients. The cored tablet combination preparatio...
|
|
WO/2024/079664A1 |
The disclosure provides compositions including a human milk oligosaccharide (HMO), as well as methods of using the same for reducing inflammation of the skin, treating or preventing psoriasis, acne, rosacea, eczema, erythema, UV radiatio...
|
|
WO/2024/077335A1 |
This invention relates to Factor IX variant polypeptides for administration to soft tissues.
|
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
|
WO/2024/054985A3 |
The invention features methods of treating a disease or condition associated with elevated activin signaling (e.g., a bone disease, pulmonary hypertension, fibrosis, a muscle disease, a metabolic disease, thrombocytopenia, or neutropenia...
|
|
WO/2024/077856A1 |
Provided in the present invention is the use of a TBX family transcription factor as a target in the preparation of a drug for treating ophthalmic diseases. In the present invention, the TBX family transcription factor is used as a targe...
|
|
WO/2024/076550A1 |
Disclosed is a method of using Netrin-1 (NTN1) driven rejuvenation of an aged hematopoietic system based on its shown dependency of reestablishing integrity of aged bone marrow niche and reactivating DNA damage response (DDR). NTN1 is sh...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
|
WO/2024/077153A1 |
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodi...
|
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/077148A1 |
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction i...
|
|
WO/2024/077159A1 |
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or mo...
|
|
WO/2024/069200A2 |
A modified protein scaffold and use thereof The invention relates to a protein comprising a limited amino acid sequence of SEQ ID NO: 115, within which a segment of the general formula Ih-mod GX1CX1VX2X3X4X5 is present where X1 is any of...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/067626A1 |
A composite, comprising: 3-hydroxybutyric acid; and one or more of potassium 3-hydroxybutyrate, or calcium 3-hydroxybutyrate, or magnesium 3-hydroxybutyrate. A composite, wherein the anion comprises 3-hydroxyvaleric acid, and the cation ...
|
|
WO/2024/066596A1 |
Provided are a rehmannia and lycium root bark decoction water extract solution, a rehmannia and lycium root bark decoction water extract paste, a rehmannia and lycium root bark decoction preparation and a preparation method therefor, and...
|
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
|
WO/2024/073056A1 |
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intest...
|
|
WO/2024/070504A1 |
Provided is a blood storage composition which can prevent the contamination of a plasma layer with DNA derived from blood cells, and can prevent, compared to the amount of a plasma before storage, a decrease in the amount of a plasma aft...
|
|
WO/2024/061097A1 |
Provided are an anti-platelet aggregation medicament and use thereof. The medicament is a compound having a structure of formula I, or a pharmaceutically acceptable salt thereof, a solvate thereof, or a deuterated substance thereof. The ...
|
|
WO/2024/064027A1 |
Disclosed herein, in part, are liquid pharmaceutical formulations and unit liquid pharmaceutical formulations comprising a loop diuretic, and a pharmaceutically acceptable excipient. In certain embodiments, the formulations include a buf...
|
|
WO/2024/061946A2 |
Provided are materials and methods for the treatment of diseases or disorders, and more particularly to the mobilization of stem cells and/or the treatment of a disease, disorder or condition involving CXCR4 receptor activity by administ...
|
|
WO/2024/064723A1 |
The present disclosure relates to methods for treating or stabilizing a traumatic brain injury (TBI) accompanied by hemorrhagic shock in a patient in need thereof by administration of oxygen reduced blood to the patient.
|
|
WO/2024/060463A1 |
The present invention relates to an optimized polynucleotide sequence encoding a human coagulation factor VIII (FVIII) polypeptide. The present disclosure also relates to an FVIII gene expression cassette, a recombinant AAV vector, and a...
|
|
WO/2024/061271A1 |
Disclosed is a biotinylated heparin pentasaccharide capable of being neutralized, which has a structure as represented by formula (I). The anti-coagulation activity of the biotinylated heparin pentasaccharide capable of being neutralized...
|
|
WO/2024/060649A1 |
The present invention provides an siRNA or a pharmaceutically acceptable salt for inhibiting the expression of TMPRSS6 in a human cell, and a proper modification is made to the siRNA to improve the silencing capability against a target a...
|
|
WO/2024/060167A1 |
The present invention provides a fusion protein, which comprises: a tissue plasminogen activator or a variant thereof; a disintegrin or a variant thereof; and a connector. The connector connects the tissue plasminogen activator or the va...
|
|
WO/2024/061172A1 |
Disclosed is a prolyl hydroxylase inhibitor, which belongs to the technical field of medicines. The present invention provides a pyridino-triazole compound having a structure represented by the formula below. The pyridino-triazole compou...
|
|
WO/2024/062986A1 |
Provided is a powder composition that can be made into a foamy food product exhibiting a masking effect and being highly dispersible in an aqueous solvent. The powder composition is to be made into a foamy food product by mixing with wat...
|
|
WO/2024/061202A1 |
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibit...
|
|
WO/2024/059494A1 |
Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD...
|
|
WO/2024/059336A1 |
Provided are methods and compositions for treating or preventing lymphedema by administering an inhibitor of the protease-activated receptor 2 (PAR2) pathway.
|
|
WO/2024/059714A1 |
The present application generally relates to a method of treating advanced hepatic fibrosis with Formulation (I). Formulation (I) is a retinoid-conjugated lipid nanoparticle (LNP) containing HSP47 siRNA which prevents HSP47 protein trans...
|
|
WO/2024/059771A1 |
The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particu...
|
|
WO/2024/054408A1 |
Provided herein are methods for treating HSCT-TMA in a particular patient sub-population (e.g., HSCT-TMA patients with body weight ≥30 kg who received a transfusion (e.g., platelet or red blood cell (RBC) transfusion) in the 4 weeks fo...
|
|
WO/2024/053350A1 |
The purpose of the present invention is to provide a method for producing an aminoazide compound and a diamine compound in which the formation of undesired diastereomers is inhibited and which has good diastereoselectivity. Provided is a...
|
|
WO/2024/053643A1 |
The specific embodiments of the present invention provide: dried plasma that is characterized by having excellent particle uniformity, retaining the activity of the various blood clotting factors, and having a D50 of 200–400 μm on a v...
|
|
WO/2024/050596A1 |
The present disclosure generally relates to methods of determining the probability of live birth and to methods of, and compositions for, increasing the probability of live birth. The methods disclosed include an analysis of the level an...
|
|
WO/2024/054436A1 |
Provided are methods of treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), e.g., TMA after HSCT, in human patients having elevated levels of thrombomodulin (TM) and syndecan-1 (SYND1) compared t...
|
|
WO/2024/051766A1 |
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
|
|
WO/2024/046420A1 |
The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...
|
|
WO/2024/049951A1 |
The disclosure provides methods for treating a human patient with sickle cell disease. These methods include administering a properdin binding antibody or antigen-binding fragment thereof to the patient.
|
|
WO/2024/046622A1 |
The invention lies in the field of delivery of nucleic acids into a cell. In particular, disclosed herein is a nucleic acid that is polyplexed with a polymeric scaffold, which is provided in combination with an endosomal escape-enhancing...
|
|
WO/2024/046355A1 |
Use of a composition including mesenchymal stem cells in the manufacture of a medicament for alleviating myelofibrosis in a subject is provided.
|
|
WO/2024/045163A1 |
A method for preparing a polyphenol-polymer composite coating, which comprises the steps of: 1) formulating a polyphenolic hydroxyl substance and a hydrophilic uncharged or hydrophilic negatively-charged polymer into a mixed solution; 2)...
|
|
WO/2024/047483A1 |
Arachidonic acid, compositions and uses thereof The present disclosure relates to arachidonic acid for use in the prevention or decrease of significant post-operative bleeding, including when an extracorporeal circulation procedure as ca...
|
